对 "COVID-19 感染后风险耐受性和皮层兴奋性降低 "的更正。

IF 4.8 1区医学 Q1 NEUROSCIENCES

CNS Neuroscience & Therapeutics Pub Date : 2024-10-11 DOI:10.1111/cns.70080

{"title":"对 \"COVID-19 感染后风险耐受性和皮层兴奋性降低 \"的更正。","authors":"","doi":"10.1111/cns.70080","DOIUrl":null,"url":null,"abstract":"Y. Wang, H. Yang, C. Wang, T. F. Yuan, and S. Zhang, “Reduced Risk Tolerance and Cortical Excitability Following COVID-19 Infection,” CNS Neuroscience & Therapeutics 30, no. 8 (2024): e14879.In the Table 1, n = 31 in both uninfected and infected group was incorrect. This should have read: n = 26 in uninfected group and n = 26 in infected group. Following is the revised table.We apologize for this error.","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"30 10","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70080","citationCount":"0","resultStr":"{\"title\":\"Correction to “Reduced Risk Tolerance and Cortical Excitability Following COVID-19 Infection”\",\"authors\":\"\",\"doi\":\"10.1111/cns.70080\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Y. Wang, H. Yang, C. Wang, T. F. Yuan, and S. Zhang, “Reduced Risk Tolerance and Cortical Excitability Following COVID-19 Infection,” CNS Neuroscience & Therapeutics 30, no. 8 (2024): e14879.In the Table 1, n = 31 in both uninfected and infected group was incorrect. This should have read: n = 26 in uninfected group and n = 26 in infected group. Following is the revised table.We apologize for this error.\",\"PeriodicalId\":154,\"journal\":{\"name\":\"CNS Neuroscience & Therapeutics\",\"volume\":\"30 10\",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70080\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS Neuroscience & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cns.70080\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70080","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

Y.Wang, H. Yang, C. Wang, T. F. Yuan, and S. Zhang, "Reduced Risk Tolerance and Cortical Excitability Following COVID-19 Infection," CNS Neuroscience & Therapeutics 30, no. 8 (2024): e14879.在表 1 中，未感染组和感染组的 n = 31 不正确。应为：未感染组 n = 26，感染组 n = 26。以下是修订后的表格。我们对这一错误表示歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to “Reduced Risk Tolerance and Cortical Excitability Following COVID-19 Infection”

Y. Wang, H. Yang, C. Wang, T. F. Yuan, and S. Zhang, “Reduced Risk Tolerance and Cortical Excitability Following COVID-19 Infection,” CNS Neuroscience & Therapeutics 30, no. 8 (2024): e14879.

In the Table 1, n = 31 in both uninfected and infected group was incorrect. This should have read: n = 26 in uninfected group and n = 26 in infected group. Following is the revised table.

We apologize for this error.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

CNS Neuroscience & Therapeutics 医学-神经科学

CiteScore

7.30

自引率

12.70%

发文量

240

审稿时长

2 months

期刊介绍： CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.